200 likes | 229 Views
Explore cancer recurrence after renal transplantation, survival rates, and comparisons with general populations. ANZDATA insights.
E N D
Recurrence of Malignancy after Transplantation ANZDATA - Australian and New Zealand Dialysis and Transplant Registry NSW Cancer Council
Donor Recipient Recurrence of MalignancyISSUES
Timing of Cancer Diagnosis PRE Dx POST Dx DIALYSIS Tx DEATH CANCER
Number of Patients with CancerANZDATA Database 1999 Cancer Pre Dx Post Dx Skin 454 777 Kidney 406 73 Myeloma 192 20 Bladder 162 93 Breast 141 66 Colon 129 56 Prostate 126 42 Melanoma 95 48 Rectal 55 20 Cervix 55 15 ALL Non skin Cancer 1718 789
Recurrence of cancer after RENAL TRANSPLANTATION ANZDATA pre transplant Cancers 1963- 1999# Tx Recurrence • Colon 23 0 • Breast 20 0 • Female genital 20 2 • Prostate 5 1 • Bladder 24 1 • Kidney 37 2 • Ureter 1 0 • Melanoma 19 2 • Lymphoma 10 0 • Myeloma 4 0 • Other non-skin 47 3 • TOTAL 210 11 • No prior Cancer 11684
Recurrence of cancer after RENAL TRANSPLANTATION ANZDATA Tx Follow Up Months Dead Dead Dead Dead Dead Dead
ANZDATA Patient survival after Renal Transplantation CD1 1985 - 1999
Diagnosis of Cancer pre-Transplant Patients at risk = 27,495 Pt Years at risk = 1,361,200
Survival after DiagnosisCancer diagnosed pre-dialysis 0 10 8 6 4 2 Median Survival in Years ANZDATA
Survival after DiagnosisCancer diagnosed post-dialysis 0 10 8 6 4 2 Median Survival in Years ANZDATA
Comparison of 5 year survival of general and dialysis populations
Breast CancerANZDATA 1999 vs NSW Cancer Databases POPULATIONS 43% 33%
MyelomaANZDATA 1999 vs NSW Cancer Databases POPULATIONS
Colon CancerANZDATA 1999 vs NSW Cancer Databases POPULATIONS
Bladder CancerANZDATA 1999 vs NSW Cancer Databases POPULATIONS
Kidney CancerANZDATA 1999 vs NSW Cancer Databases POPULATIONS
MelanomaANZDATA 1999 vs NSW Cancer Databases POPULATIONS
LymphomaANZDATA 1999 vs NSW Cancer Databases POPULATIONS
Lymphoma Bladder Melanoma Colon Kidney Breast
Cancer in Uraemic populations • ANZDATA - are the data real? • review of all cases • review causes of death • review metastasis diagnoses • review therapy Acknowledgements: Brian Livingston, Ross Sheil